Trending Now
- “I will soon make an announcement regarding a statewide tour across Tamil Nadu.” – O. Panneerselvam.
- Vatsala, Asia’s oldest elephant, has passed away at Panna Tiger Reserve; social activists mourn the death of this elephant, which lived for over 100 years.
- “The U.S. Govt earned ₹8 lakh crore this year through increased tariffs on foreign goods.” – U.S President Donald Trump.
- World No.1 Aryna Sabalenka has advanced to the semifinals in the Women’s Singles category at Wimbledon Tennis.
Businesswire
Eurofins Announces Acquisition of Assets of Gomti Life Sciences
February 5, 2020
Business Wire IndiaEurofins, through Eurofins Advinus, acquires all assets of Gomti Life Sciences Private Limited through a Business Transfer Agreement. The assets include a fully equipped state-of-the-art manufacturing facility located in Bidadi Industrial Area, Bangalore, India, with cGMP pilot plant, intermediate area and ISO class 8 clean rooms and a total reactor capacity of about 45 KL.
With this acquisition, Eurofins Advinus will be able to manufacture RSMs, intermediates, APIs and NCEs. The company can now support drug substance requirements from multi kilogram to MT scale for Toxicology studies, clinical trials and launch quantities.
Rajiv Malik, MD of Eurofins Advinus Limited commented: This acquisition could be a game changer for Eurofins Advinus as it enables the group to enter clinical development and commercial supply part of the Pharma R&D value chain through cGMP API supplies of NCEs. This addition is also a part of a larger foray of the Eurofins group into CDMO / CRAMS market.
Source: Businesswire
With this acquisition, Eurofins Advinus will be able to manufacture RSMs, intermediates, APIs and NCEs. The company can now support drug substance requirements from multi kilogram to MT scale for Toxicology studies, clinical trials and launch quantities.
Rajiv Malik, MD of Eurofins Advinus Limited commented: This acquisition could be a game changer for Eurofins Advinus as it enables the group to enter clinical development and commercial supply part of the Pharma R&D value chain through cGMP API supplies of NCEs. This addition is also a part of a larger foray of the Eurofins group into CDMO / CRAMS market.
Source: Businesswire
